BG Medical Technologies to Highlight Role of Galectin-3 Testing in Reducing Unplanned Hospital Readmissions at the 2012 American Heart Association Scientific Sessions  
11/5/2012 9:28:38 AM

WALTHAM, Mass. and LOS ANGELES, Nov. 5, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, today announced that it will be launching a major initiative to help hospitals reduce the number of unplanned readmissions for heart failure patients, beginning at the American Heart Association (AHA) Scientific Sessions 2012 taking place Nov. 3-7, 2012 in Los Angeles, California. Representatives at the BG Medicine booth (#1737) will be on hand to highlight the role that galectin-3 blood testing can play in helping hospitals address the urgent need to reduce readmission rates.